Contemporary Use of Oral Antithrombotic Agents: Focus on Dual and Triple Therapeutic Approaches

Atherosclerotic cardiovascular disease (ASCVD) represents a long‐standing health care burden in most industrialized countries. Management of ASCVD is multifaceted, and utilization of antithrombotic agents is a key component of care to reduce vascular events. Minimizing thrombotic risk can be accompl...

Full description

Saved in:

Bibliographic Details
Published in:	Pharmacotherapy Vol. 37; no. 12; pp. 1545 - 1564
Main Authors:	Jenkins, Antoine T., Kantorovich, Alexander, Burman, Luba
Format:	Journal Article
Language:	English
Published:	United States Wiley Subscription Services, Inc 01-12-2017
Subjects:	Anticoagulants Anticoagulants - adverse effects Anticoagulants - therapeutic use anticoagulation antiplatelet Antiplatelet therapy Arteriosclerosis aspirin atherosclerosis bleeding Cardiovascular diseases Complications direct oral anticoagulants (DOACs) Drug Therapy, Combination - adverse effects Fibrinolytic Agents - adverse effects Fibrinolytic Agents - therapeutic use Guidelines as Topic Hemorrhage - chemically induced Humans P2Y12 inhibitor Platelet Aggregation Inhibitors - adverse effects Platelet Aggregation Inhibitors - therapeutic use thrombosis Thrombosis - drug therapy atherosclerosis bleeding thrombosis P2Y12 inhibitor anticoagulation aspirin direct oral anticoagulants (DOACs) antiplatelet
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Atherosclerotic cardiovascular disease (ASCVD) represents a long‐standing health care burden in most industrialized countries. Management of ASCVD is multifaceted, and utilization of antithrombotic agents is a key component of care to reduce vascular events. Minimizing thrombotic risk can be accomplished via antiplatelet or anticoagulant drugs; however, combination therapy is warranted for some indications. Although reducing thrombotic complications is important, it is equally vital to consider the safety of combination regimens. Thus clinicians must effectively balance both individualized thrombotic and bleeding risks when using this strategy. Scenarios occur in practice when determining the role for combination therapy is not clear, especially for patients with ASCVD who require both dual antiplatelet therapy plus anticoagulation. The aim of this review is to discuss the role of dual or triple antithrombotic therapies across the spectrum of thrombotic disease states. In addition to critiquing relevant research studies and evaluating key recommendations from nationally published guidelines and consensus statements involving the use of these agents, we offer practical considerations that can be utilized when managing patients with ASCVD.
Bibliography:	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23
ISSN:	0277-0008 1875-9114
DOI:	10.1002/phar.2041